As shown in Figure 3, analysis in subgroups did not markedly improve the prediction in overall survival in subgroups with different hormone receptor status, suggesting that this signature may operate well irrespective of the receptor status of breast cancer. This evidence concerns the gene NR4A1 and breast cancer.